Zai Lab Ltd

Zai Lab Limited announced its second quarter 2026 financial results, reporting total revenues of $106.3 million and a net loss of $50.8 million. Despite a year-over-year revenue decrease, net product revenue grew 11% sequentially. The company highlighted significant pipeline advancements, including multiple Orphan Drug and Fast Track Designations for zocilurtatug pelitecan (zoci), NMPA approval for TIVDAK in China, and the successful commercial launch of KarXT in mainland China. Zai Lab anticipates several key clinical and regulatory milestones in late 2026 and early 2027.

Zai Lab Limited announced that Josh Smiley ceased serving as President and Chief Operating Officer, effective May 18, 2026, with his last day of employment set for May 22, 2026. His responsibilities have been taken over by Samantha Du, the Company's Board Chair, Founder, and Chief Executive Officer, along with other members of the management team. Mr. Smiley will receive severance in accordance with his existing employment agreement.

Zai Lab Limited reported total revenues of $99.6 million for the first quarter of 2026, a 6% decrease year-over-year, primarily due to competitive impacts on ZEJULA and pricing adjustments for VYVGART. The company's net loss increased to $51.0 million. Despite the financial decline, Zai Lab highlighted significant pipeline progress, including standout data for zocilurtatug pelitecan (zoci) in SCLC and epNECs, new collaborations for zoci, positive Phase 3 readouts for povetacicept in IgAN and elegrobart in TED, and ongoing preparations for the KarXT launch in China.

Zai Lab Ltd (ZLAB) announced its 2026 Annual General Meeting of Shareholders will be held on Wednesday, June 17, 2026, both physically in Shanghai and virtually. Shareholders will vote on the re-election of nine directors, the appointment of KPMG LLP and KPMG as independent auditors for 2026, and an advisory vote on executive compensation. Additionally, proposals include approving general mandates for the Board to allot and issue shares and to repurchase shares, each up to 10% of the total issued shares.